Opko: Contrarian Play On Positive Update

  • Opko provided positive update for its Phase 3 hGH-CTP study.
  • The update clears doubts about data released in December last year.
  • The stock is very attractively priced after losing considerable value over December data issue.

By S. Mitra, MBA (ISB)

Opko Healthcare (NASDAQ:OPK) stock offers a good buying opportunity at its current beaten down price due to a number of reasons. The company recently provided an encouraging update about its hGH-CTP Phase 3 setback that happened in December last year. Opko also initiated a Phase 3 study for hGH-CTP in the pediatric segment. This positive news is expected to get the stock out of its rut. Further, the stock is also expected to benefit from positive revenue growth for the company's newly launched Rayaldee product.

The full post is available to investor members only. Subscribe here.